|
Feb 24
|
Sanofi/Teva Unveil New Detailed Data For Duvakitug Study Supporting Overall Efficacy For Common Inflammatory Bowel Disease
|
|
Feb 24
|
Teva and Alvotech launch ustekinumab biosimilar injection in US
|
|
Feb 24
|
Sanofi and Teva report new outcomes from Phase IIb trial of duvakitug
|
|
Feb 22
|
Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn’s Disease
|
|
Feb 21
|
Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.
|
|
Feb 20
|
Billionaire Stanley Druckenmiller Dumped Duquesne's Entire Stake in Broadcom and Bought One of Wall Street's Hottest Drug Stocks Hand Over Fist
|
|
Feb 19
|
Is Teva Pharmaceutical (TEVA) Trading at a Discount?
|
|
Feb 18
|
Teva to Host Conference Call on February 24, 2025 to Discuss New Data Presented for Duvakitug (anti-TL1A) Positive Phase 2b results at the 20th Annual Congress of the European Crohn's and Colitis Organisation (ECCO)
|
|
Feb 18
|
FDA To Review Teva and Alvotech Drug That Could Compete With Regeneron's Eylea
|
|
Feb 18
|
Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)
|
|
Feb 14
|
Stanley Druckenmiller's Strategic Moves: A Closer Look at Teva Pharmaceutical Industries Ltd
|
|
Feb 11
|
Axsome Stock Surges 20% on Auvelity Patent Settlement With Teva
|
|
Feb 10
|
Axsome Therapeutics Resolves Generic Patent Litigation With Teva Over Depression Drug, Analyst Maintains Axsome As 'Top Pick For 2025'
|
|
Feb 10
|
Axsome secures top drug’s future with Teva patent settlement
|
|
Jan 3
|
Why Teva Pharmaceuticals Industries Ltd. (TEVA) Crashed Yesterday
|
|
Nov 8
|
Teva to Present at the Jefferies London Healthcare Conference
|
|
Nov 8
|
Are Investors Undervaluing Teva Pharmaceutical Industries (TEVA) Right Now?
|
|
Nov 7
|
Amicus' Q3 Earnings & Revenues Beat Estimates, '24 View Updated
|
|
Nov 7
|
TEVA Stock Down 7% Despite Q3 Earnings & Sales Beat, Guidance Increase
|
|
Nov 7
|
Teva Pharmaceutical Industries Ltd (TEVA) Q3 2024 Earnings Call Highlights: Strong Revenue ...
|